CorMedix(NASDAQ) CRMD

CorMedix Inc. helps patients avoid dangerous infections from medical tubes. Its primary product stops germs and clots in medical catheters. This technology protects vulnerable people receiving long-term hospital care.

Fighting Infections in the Clinic

• DefenCath: Anti-infective solution designed to prevent bloodstream infections and clots in patients using central venous catheters for hemodialysis; generated $66.1 million in net sales during the second quarter of 2026.
• Melinta Portfolio: Diverse group of hospital-focused treatments for infectious diseases, including products such as VABOMERE and REZZAYO; contributed $28.2 million to net sales in the second quarter of 2026.
• Grant Income: Revenue earned under an agreement with the Biomedical Advanced Research and Development Authority for medical development; totaled $5.1 million in the first half of 2026.
• Contract Revenue: Income from milestone payments and royalties earned through licensing agreements for various pharmaceutical products.

Strategic Moves and Trials

• Acquired the Melinta business on Aug. 29, 2025, to expand its portfolio into hospital-focused infectious disease treatments.
• Announced positive Phase III clinical trial results for REZZAYO on April 27, 2026, for potential use in stem cell transplant patients.
• Initiated efforts to move product manufacturing to the United States in 2026 to reduce costs and mitigate risks from new tariffs.
• Defended the patents for its MINOCIN for Injection product in a federal appeals court ruling on June 8, 2026.

What Makes CorMedix Different

The company maintains a specialized focus on preventing infections in clinical settings through a combination of internal drug development and acquired pharmaceutical brands. Its strategy relies on navigating complex government reimbursement systems and protecting its intellectual property through legal and regulatory channels.

By the Numbers

• Total revenue and grant income reached $101.9 million for the three-month period ended June 30, 2026, up 157% year over year.
• Net income was $26.0 million for the three-month period ended June 30, 2026, representing a 31% increase year over year.
• Cash, cash equivalents, and short-term investments totaled $256.7 million as of June 30, 2026.
• Research and development expenses rose 174% to $6.7 million during the second quarter of 2026 to support new clinical trials.
• The company had 191 full-time employees and a market capitalization of $557.0 million as of mid-2026.

Bottom Line

CorMedix has transitioned from a development-stage firm into a commercial biopharmaceutical company with a diversified portfolio of infectious disease treatments. The integration of the Melinta acquisition and the commercial rollout of DefenCath provide a broader foundation for addressing life-threatening conditions in hospital environments.